Material Event Form 8 K

Item 8.01 Other Events

MIRA Pharmaceuticals Reports Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments in Preclinical Study

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announces that in a recent study, its oral ketamine analog, Ketamir-2, demonstrated significantly greater efficacy than FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica) in recent preclinical models of neuropathic pain.

The Company is actively conducting additional studies focused on chemotherapy-induced and diabetic neuropathy. These studies are part of the broader development program, which also includes plans to initiate PTSD trials. Notably, MIRA Pharmaceuticals is exploring government funding opportunities to support the PTSD program.

The Company remains on track to submit an Investigational New Drug (IND) application by the end of 2024, with Phase I clinical trials expected to begin in Q1 2025. Phase II trials are projected to start by late 2025.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "plans," "anticipate," "believe," "estimate," "continue" and similar words. Such statements are only predictions and actual events or results may differ materially from those anticipated in these forward-looking statements. You should not place undue reliance on any forward-looking statements. In this report, such forward-looking statements relate to the anticipated benefits of the Company's preclinical testing results for, and the time for regulatory filings related to, Ketamir-2 or Nor-Ketamir-2. Readers are cautioned that actual future results related to Ketamir-2 or Nor-Ketamir-2 may deviate materially and adversely from the forward-looking statements regarding Ketamir-2 and Nor-Ketamir-2 contained herein. The Company does not assume any obligation to update forward-looking statements as circumstances change, except as required by securities laws. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.